Surmodics, Inc. (NASDAQ:SRDX) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations And Financial Condition.

On November 16, 2016, Surmodics, Inc. (the Company),
issued a press release (the Press Release) announcing the
results for the quarter ended September 30, 2016. A copy of the
full text of the Press Release is furnished as Exhibit 99.1 to
this report.

The information contained in this Item 2.02, including Exhibit
99.1, shall not be deemed to be filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, nor shall
they be deemed to be incorporated by reference into any filing
under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

About Surmodics, Inc. (NASDAQ:SRDX)

SurModics, Inc. is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company is focused on to transform its medical device business from being a provider of coating technologies to offering whole product solutions to medical device customers. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. Its products include BioFX Liquid Nova-Stop Solution, StabilZyme Protein-Free AP Stabilizer, StabilZyme Protein-Free Stabilizer and StabilBlot Blocker Family.

Surmodics, Inc. (NASDAQ:SRDX) Recent Trading Information

Surmodics, Inc. (NASDAQ:SRDX) closed its last trading session down -1.51 at 25.89 with 54,618 shares trading hands.